Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

por Ebdrup, Bjørn H, Knop, Filip K, Ishøy, Pelle L, Rostrup, Egill, Fagerlund, Birgitte, Lublin, Henrik, Glenthøj, Birte
Publicado 2012

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral...

por Eriksson, Robert, Broberg, Brian V., Ishøy, Pelle L., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Knop, Filip K., Ebdrup, Bjørn H.
Publicado 2019

Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

por Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Publicado 2016

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded inter...

por Ishøy, Pelle L, Knop, Filip K, Broberg, Brian V, Baandrup, Lone, Fagerlund, Birgitte, Jørgensen, Niklas R, Andersen, Ulrik B, Rostrup, Egill, Glenthøj, Birte Y, Ebdrup, Bjørn H
Publicado 2014